It competes with p-aminobenzoic acid for dihydrofolate synthase, inhibits bacterial synthesis of dihydrofolate, and when used in combination with trimethoprim, it has a double blocking effect on bacterial synthesis of tetrahydrofolate, thus enhancing the antibacterial effect.

It competes with p-aminobenzoic acid for dihydrofolate synthase, inhibits bacterial synthesis of dihydrofolate, and when used in combination with trimethoprim, it has a double blocking effect on bacterial synthesis of tetrahydrofolate, thus enhancing the antibacterial effect.

By inhibiting bacterial dihydrofolate reductase, it hinders the reduction of dihydrofolate to tetrahydrofolate. When used in combination with sulfonamides, it has a double blocking effect on the bacterial synthesis of tetrahydrofolate, thus enhancing the antibacterial effect.

1. It can simultaneously relax the coronary arteries in the normal blood supply area and the ischemic area, antagonize spontaneous or ergonovine-induced coronary artery spasm, increase the delivery of myocardial oxygen to patients with coronary artery spasm, and relieve and prevent coronary artery spasm. 2. It can inhibit myocardial contraction, reduce myocardial metabolism, and reduce myocardial oxygen consumption. 3. It can relax peripheral resistance vessels, reduce peripheral resistance, reduce systolic and diastolic blood pressure, and reduce cardiac afterload. 4. It can delay the sinus node function and atrioventricular conduction of the isolated heart; electrophysiological studies on whole animals and humans have not found that this product has the effect of delaying atrioventricular conduction, prolonging the recovery time of the sinus node, and slowing down the sinus node rate.

This product is a non-steroidal anti-inflammatory analgesic that has anti-inflammatory effects such as inhibiting prostaglandin synthase, inhibiting inflammatory exudation, and reducing redness and swelling. It can also inhibit the formation and release of RGE, histamine, 5-hydroxytryptamine, etc. in local inflamed tissues and reduce the inflammatory pain effects of inflammatory transmitters.

Rifampicin is a semi-synthetic broad-spectrum antibacterial drug of the rifamycin class, which has antibacterial activity against a variety of pathogenic microorganisms. The drug has a significant bactericidal effect on Mycobacterium tuberculosis and some non-tuberculous mycobacteria (including Mycobacterium leprae, etc.) both inside and outside the host cells. It has a good antibacterial effect on aerobic Gram-positive bacteria, including enzyme-producing strains of Staphylococcus aureus and methicillin-resistant strains, Streptococcus pneumoniae, other Streptococcus, Enterococcus, Listeria, Bacillus anthracis, Clostridium perfringens, Corynebacterium diphtheriae, anaerobic cocci, etc. It also has a high degree of antibacterial activity against aerobic Gram-negative bacteria such as Neisseria meningitidis, Haemophilus influenzae, and Neisseria gonorrhoeae. It also has a good effect on Legionella, and has an inhibitory effect on pathogens such as Chlamydia trachomatis, lymphogranuloma venereum, and psittacosis.

Trimethoprim (TMP) is an antibacterial agent, a lipophilic weak base, and its chemical structure belongs to the pyrimethamine class. It has antibacterial activity against Escherichia coli, Klebsiella, Proteus mirabilis, Salmonella, and Shigella, but has no obvious antibacterial effect on Streptococcus pneumoniae, Neisseria gonorrhoeae, and Neisseria meningitidis, and has no effect on Pseudomonas aeruginosa. The mechanism of action of this product is to interfere with bacterial folic acid metabolism. It mainly selectively inhibits the activity of bacterial dihydrofolate reductase, so that dihydrofolate cannot be reduced to tetrahydrofolate, and synthetic folic acid is the main component of nucleic acid biosynthesis. Therefore, this product prevents the synthesis of bacterial nucleic acids and proteins, and the binding of this product to bacterial dihydrofolate reductase is 50,000 to 60,000 times tighter than that to mammalian enzymes. The combination of this product and sulfonamides can double block the bacterial folic acid synthesis metabolism, have a synergistic effect, enhance the antibacterial activity of sulfonamides, and convert the antibacterial effect into a bactericidal effect, reducing the production of drug-resistant strains.